A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 26, Issue 5, 2001, Pages 423-434

  Coull, Jason J ^a   Turner, Diana ^b   Melby, Thomas ^c   Betts, Michael R ^a   Lanier, Randall ^c   Margolis, David M ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Dallas   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Antiretroviral resistance; HIV 1; Mycophenolate mofetil; Mycophenolic acid

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; CD3 ANTIGEN; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; FOSCARNET; GANCICLOVIR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEINASE INHIBITOR; RITONAVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MULTIDRUG RESISTANCE; NAUSEA; NEUROPATHY; PRIORITY JOURNAL; SALVAGE THERAPY; VIRUS ACTIVATION;

EID: 0035870543     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200104150-00004     Document Type: Article

References (39)

1. Gao WY, Johns DG, Mitsuya H. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′, 3′-dideoxynucleosides. Mol Pharmacol 1994;46:767-72.
2. Lori F, Rosenberg E, Lieberman J, et al. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters. AIDS Res Hum Retroviruses 1999;15-1333-8.
3. Foli A, Maserati R, Minoli L, et al. Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine [letter]. AIDS 1998;12:1 113-4.
4. Lori F, Jessen H, Foli A, et al. Long-term suppression of HIV-1 by hydroxyurea and didanosine [letter]. JAMA 1997;277:1437-8.
5. Rutschmann OT, Opravil M, Iten A, et al. Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study. Antiviral Ther 1998;3: 65-7.
6. Maserati R. Hydroxyurea in the treatment of HIV-1 infection: toxicity and side effects. J Biol Regul Homeost Agents 1999;13:181-5.
7. Seminari E, Lisziewicz J, Tinelli C, et al. Hydroxyurea toxicity combined with didanosine (ddl) in HIV-1-seropositive asymptomatic individuals. Int J Clin Pharmacol Ther 1999;37:514-518.
8. Faletto MB, Miller WH, Garvey EP, et al. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother 1997;41:1099-1107.
9. Allison AC, Kowalski WJ, Muller CD, et al. Mechanisms of action of mycophenolic acid. Ann NY Acad Sci 1993;696:63-87.
10. Allison AC, Eugui EM, Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996;10:77-84.
11. Carr SF, Papp E, Wu JC, et al. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993;268:27286-90.
12. Ichimura H, Levy JA. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. Virology 1995;211:554-60.
13. Mitchell BS, Dayton JS, Turka LA, et al. IMP dehydrogenase inhibitors as immunomodulators. Ann NY Acad Sci 1993;685: 217-24.
14. Margolis D, Heredia A, Gaywee J, et al. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr 1999;21:362-70.
15. Heredia A, Margolis D, Oldach D, et al. Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1 [letter] [published erratum appears in J Acquir Immune Defic Syndr 2000 Jan 1;23:105]. J Acquir Immune Defic Syndr 1999;22:406-7.
16. Allison AC, Almquist SJ, Muller CD, et al. In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443. Transplant Proc 1991;23:10-14.
17. Fulton B, Markham A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996;51:278-98.
18. Parker G, Bullingham R, Kamm B, et al. Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharmacol 1996;36-332-44.
19. Bullingham R, Monroe S, Nicholls A, et al. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996;36:315-24.
20. Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 1996;28:925-9.
21. Gummert JF, Barten MJ, Sherwood SW, et al. Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. J Pharmacol Exp Ther 1999;291:1100-12.
22. Laliberte J, Yee A, Xiong Y, et al. Effects of guanine nucleotide depletion on cell cycle progression in human T lymphocytes. Blood 1998;91:2896-2904.
23. Weigel G, Bertalanffy P, Dubsky P, et al. Mycophenolic acid influences T helper 2 (Th2) cytokine induced expression of intercellular cell adhesion molecule-1 (ICAM-1) on human endothelial cells. Clin Chem Lab Med 1999;37:253-7.
24. Martin SJ, Reutelingsperger CP, McGahon AJ, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995;182:1545-56.
25. Wasmuth JC, Klein KH, Hackbarth F, et al. Prediction of imminent complications in HIV-1-infected patients by markers of lymphocyte apoptosis. J Acquir Immune Defic Syndr 2000;23:44-51.
26. Marzio R, Mauel J, Betz-Corradin S. CD69 and regulation of the immune function. Immunopharmacol Immunotoxicol 1999;21: 565-82.
27. Testi R, D'Ambrosio D, De Maria R, et al. The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. Immunol Today 1994;15:479-83.
28. Ziegler SF, Ramsdell F, Alderson MR. The activation antigen CD69. Stem Cells 1994;12:456-65.
29. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-5.
30. Ju ST, Matsui K, Ozdemirli M. Molecular and cellular mechanisms regulating T and B cell apoptosis through Fas/FasL interaction. Int Rev Immunol 1999;18:485-513.
31. Peter ME, Ehret A, Berndt C, et al. AIDS and the death receptors. Br Med Bull 1997;53:604-16.
32. + T cell count, and HIV plasma viral copy number. AIDS Res Hum Retroviruses 1999;15:1509-18.
33. Falloon J, Piscitelli S, Vogel S, et al. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin Infect Dis 2000;30:313-18.
34. Chapuis AG, Paolo Rizzardi G, D'Agostino C, et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 2000;6:762-8.
35. Cohn RG, Mirkovich A, Dunlap B, et al. Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation 1999;68:411-8.
36. + T cells in tonsillar tissue in HIV type 1 infection. AIDS Res Hum Retroviruses 1998;14:1635-43.
37. +) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood 1999;94:1021-7.
38. Stoddart CA, Lieger T, Lindquisst-Stepps VD, et al. Impaired replication of protease-resistant HIV-1 in human thymus. Keystone Symposia: novel biological approaches to HIV-1 infection based on new insights into HIV biology, Keystone, Colorado, U.S.A., 2000.
39. + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000;181:946-53.